Nephrotic Syndrome Global Market Report 2025

The nephrotic syndrome market size has grown rapidly in recent years. It will grow from $0.87 billion in 2024 to $00.96 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth during the historic period can be attributed to the rising incidence of nephrotic syndrome, an increase in genetic disorders, growing obesity rates, the expanded use of immunosuppressive medications, and the increasing impact of genetic factors.

The nephrotic syndrome market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth during the forecast period can be attributed to increasing awareness of nephrotic syndrome, a rising prevalence of chronic kidney disease (CKD), a growing incidence of metabolic disorders, an aging population, and a higher occurrence of autoimmune diseases. Key trends in the forecast period include the expansion of telemedicine and remote monitoring, advancements in drug delivery systems, innovations in treatment modalities, progress in biotechnology, and the integration of digital health technologies.

The rising prevalence of kidney diseases is expected to drive the growth of the nephrotic syndrome market. Kidney diseases encompass various conditions that impair the kidneys' ability to filter waste and excess fluids from the blood. Factors contributing to the increasing incidence of kidney diseases include diabetes, hypertension, obesity, aging populations, and lifestyle changes such as high sodium intake and inadequate hydration. Nephrotic syndrome exacerbates kidney diseases by damaging the glomeruli, impairing filtration and protein retention. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that the percentage of chronic kidney disease (CKD) mortality in the country increased from 4.2% in 2021 to 6.2% in 2022. As a result, the growing prevalence of kidney diseases is fueling the expansion of the nephrotic syndrome market.

Leading companies in the nephrotic syndrome market are prioritizing the development of innovative formulations, such as loop diuretic injections, to enhance fluid management and reduce edema in nephrotic syndrome patients. Loop diuretic injection is an injectable medication that blocks sodium and chloride reabsorption in the loop of Henle, promoting rapid urine production. It is commonly used to treat conditions such as acute pulmonary edema, heart failure, and severe hypertension by reducing fluid overload. For instance, in March 2024, Avenacy Inc., a US-based pharmaceutical company, launched furosemide for injection in the U.S., a generic equivalent to Lasix, which received approval from the Food and Drug Administration for treating edema related to heart failure, liver cirrhosis, and kidney diseases. Packaged in 25-unit packs of 100 mg/10 mL doses, this launch is part of Avenacy's broader strategy to expand its injectable medication portfolio, with plans to introduce more than 20 products in 2024. This drug is indicated for adult and pediatric patients with edema associated with congestive heart failure, liver cirrhosis, and renal disease, including nephrotic syndrome.

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics for $3.5 billion. This acquisition aims to strengthen Novartis’ renal portfolio by incorporating Chinook Therapeutics’ late-stage assets, atrasentan and zigakibart, which are being developed for the treatment of Immunoglobulin A Nephropathy (IgAN). The acquisition aligns with Novartis’ strategic focus on innovative medicines. Chinook Therapeutics, a US-based biopharmaceutical company, specializes in developing treatments for nephrotic syndrome.

Major players in the nephrotic syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, Asahi Kasei Corporation, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Mallinckrodt Company, Evotec SE, Travere Therapeutics Inc., Aurinia Pharmaceuticals Inc., Orbis Biosciences Inc., Alpine Immune Sciences, Kezar Life Sciences, Zenyaku Kogyo Co. Ltd.

North America was the largest region in the nephrotic syndrome market in 2024. The regions covered in nephrotic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nephrotic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nephrotic syndrome is a kidney disorder characterized by excessive protein loss in the urine (proteinuria), low blood protein levels (hypoalbuminemia), high cholesterol levels (hyperlipidemia), and swelling (edema), particularly in the legs, feet, and around the eyes. It results from damage to the glomeruli, the kidney’s filtering units, allowing protein to leak into the urine.

The primary types of nephrotic syndrome treatment include drugs and devices. Drugs are substances used to diagnose, treat, or prevent diseases by modifying bodily functions. Diagnosis of nephrotic syndrome involves various tests, such as urinalysis, glomerular filtration rate (GFR) measurement, blood tests, kidney biopsy, and computerized tomography (CT) scans. The key applications span clinics, hospitals, specialty centers, and other healthcare facilities.

The nephrotic syndrome market research report is one of a series of new reports that provides nephrotic syndrome market statistics, including the nephrotic syndrome industry global market size, regional shares, competitors with the nephrotic syndrome market share, detailed nephrotic syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the nephrotic syndrome industry. This nephrotic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nephrotic syndrome market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, dialysis services, and kidney transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nephrotic syndrome market also includes sales of diuretics, anticoagulants, immunosuppressants, ACE inhibitors and Arbs and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.